Novartis Acquires AveXis for $8.7 Billion

On May 15, 2018, Novartis announced its completed acquisition of AveXis, a clinical-stage gene therapy biotech company, for a total of $8.7 billion in cash through a merger of its indirect wholly owned subsidiary, Novartis AM Merger Corporation (Merger Sub), with and into AveXis. The merger wasOriginal Article